ICON Forms Clinical Development Partnership with Mereo BioPharma
Contract research organization ICON plc announced a partnership with Mereo BioPharma Group, a specialty biopharmaceutical company.
Contract research organization ICON plc announced a partnership with Mereo BioPharma Group, a specialty biopharmaceutical company. Under this partnership, ICON will be the sole provider of clinical development services to Mereo.
Mereo is a new UK company that is focused on acquiring, developing and commercializing medicines that are targeted at rare and specialist disease areas. The company’s initial portfolio consists of clinical-stage products acquired from Novartis and are targeted at brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease and hypogonadotropic hypogonadism.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
